Equities

ImExHS Ltd

ImExHS Ltd

Actions
Health CareHealth Care Providers
  • Price (AUD)0.4175
  • Today's Change0.00 / 0.00%
  • Shares traded9.36k
  • 1 Year change-33.73%
  • Beta1.1680
Data delayed at least 20 minutes, as of Nov 13 2024 04:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IMEXHS Limited is an Australia-based provider of medical imaging software and radiology services in 18 countries, including Colombia, the United States and Australia. The Company develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The Company's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.

  • Revenue in AUD (TTM)24.68m
  • Net income in AUD-3.42m
  • Incorporated2001
  • Employees400.00
  • Location
    ImExHS Ltd122 O'Riordan StreetMASCOT 2020AustraliaAUS
  • Phone+61 29030-0040
  • Fax+61 89486-4799
  • Websitehttp://omnimarkettide.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Uscom Ltd3.77m-2.07m11.27m11.00--3.60--2.99-0.0118-0.01180.02140.01250.73160.887411.28---40.23-30.60-53.05-36.9783.8086.20-54.99-53.502.54-17.760.2443--38.730.997719.92---12.44--
Atomo Diagnostics Ltd4.24m-6.85m13.42m----1.33--3.17-0.0108-0.01080.00670.01580.30441.253.09---49.17-31.42-54.41-34.2041.4842.58-161.56-120.994.84--0.0083--66.6351.0131.23---54.38--
Control Bionics Ltd5.97m-5.91m16.34m----2.10--2.74-0.0381-0.03810.03740.03150.67322.412.98---66.73-41.07-85.40-45.9775.6268.78-99.13-92.331.40-112.620.133--2.0846.24-5.02--67.72--
Resonance Health Ltd8.80m169.31k17.47m18.00111.761.5526.171.980.00030.00030.01880.02450.5631--5.08--1.08-3.191.40-3.56----1.92-7.63----0.2527--95.1519.18121.70-33.171.63--
Singular Health Group Ltd945.75k-2.88m18.82m----12.35--19.89-0.018-0.03080.00630.00740.35368.7322.14---107.62---331.71--124.56---304.36--2.42--0.1316--112.26--42.12------
ImExHS Ltd24.68m-3.42m19.05m400.00--1.26--0.7718-0.0794-0.07940.57130.33141.1097.113.7861,692.52-15.28-22.17-20.83-29.2131.9529.75-13.85-31.201.53-4.580.0593--14.7926.48-37.97--5.61--
Lumos Diagnostics Holdings Ltd17.25m-13.32m23.86m----1.49--1.38-0.0276-0.02760.0350.02150.4264.377.02---32.88-40.29-54.62-58.0763.7749.44-77.19-151.150.6949-6.010.5314--5.6619.534.22---47.99--
Data as of Nov 13 2024. Currency figures normalised to ImExHS Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.